Rhode Island Division of Commercial Licensing and Regulation

2023 APS UPRT Scholarship Recipient Completes Advanced Aviation Safety Training

Retrieved on: 
Friday, June 30, 2023
Rhode Island Division of Commercial Licensing and Regulation, MESA, CFI, UPRT, APS, Aviation, Fatality, Aircraft, Risk, Control, Knowledge, Aviation Performance Solutions, Safety, Satellite navigation device, Airline

MESA, Ariz., June 30, 2023 /PRNewswire-PRWeb/ -- Aviation Performance Solutions LLC (APS), the global leader in Upset Prevention and Recovery Training (UPRT), is pleased to announce that 2023 APS UPRT Scholarship winner Alyssa Bodwin has completed her Professional Pilot UPRT course. Having successfully mastered this advanced aviation training, Alyssa is now among elite pilots who are equipped to recognize, prevent or recover from an aircraft upset. In addition, she has developed and refined advanced manual flight operations skills and overall airmanship, making her among the safest and most qualified of up and coming pilots.

Key Points: 
  • Up and coming pilot Alyssa Bodwin, recipient of the 2023 Upset Prevention and Recovery Training (UPRT) scholarship from Aviation Performance Solutions (APS), has successfully completed this advanced safety training course to mitigate the number one fatal threat every pilot faces, Loss of Control In-flight (LOC-I).
  • MESA, Ariz., June 30, 2023 /PRNewswire-PRWeb/ -- Aviation Performance Solutions LLC (APS), the global leader in Upset Prevention and Recovery Training (UPRT), is pleased to announce that 2023 APS UPRT Scholarship winner Alyssa Bodwin has completed her Professional Pilot UPRT course.
  • Having successfully mastered this advanced aviation training, Alyssa is now among elite pilots who are equipped to recognize, prevent or recover from an aircraft upset.
  • Each year, APS awards the UPRT Scholarship to a deserving pilot currently in flight school or starting their professional aviation career.

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, February 28, 2023
Merck Group, Civil service commission, Therapy, Conference call, GSK, Merck, Sodium-dependent phosphate transport protein 2B, MRSN, Ovarian cancer, Research, Spacecraft, Maintenance, BLA, Webcast, FDA, Patient, Carboplatin, R, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Janssen, ORR, Conference, ADC, DAR, HER2, Cancer, European Commission, Rhode Island Division of Commercial Licensing and Regulation, Breast, Food, G&A, Platinum, Pharmaceutical industry, Fine chemical, Video game, Cryptocurrency

Collaboration revenue for the fourth quarter of 2022 was $14.7 million, compared to an immaterial amount for the same period in 2021.

Key Points: 
  • Collaboration revenue for the fourth quarter of 2022 was $14.7 million, compared to an immaterial amount for the same period in 2021.
  • General and administrative (G&A) expenses for the fourth quarter of 2022 were $14.8 million, compared to $10.7 million during the same period in 2021.
  • Included in fourth quarter 2022 G&A expenses were $2.5 million in non-cash stock-based compensation expenses.
  • ET to discuss business updates and its financial results for the fourth quarter and full year 2022.

Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
NGS, JD, Depreciation, Doctor of Philosophy, DNA, MBBS, Merck, National Center for Advancing Translational Sciences, General Administration of Press and Publication, Genomics, Metabolism, Investigational New Drug, Workforce, Partnership, IND, IEM, EPI, Terminal deoxynucleotidyl transferase, Exocrine pancreatic insufficiency, Steatorrhea, Mass meeting, Patient, R, Fabry disease, MAI, Enzyme, PKU, Probability, Synthetic biology, ROFN, Serum, Doctor of Science, Takeda Pharmaceutical Company, General counsel, Rhode Island Division of Commercial Licensing and Regulation, Administration, Roche, Cryptocurrency, Pharmaceutical industry, Fine chemical, Video game, Phenylketonuria, Takeda, Fabry, Codexis, Science

REDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.

Key Points: 
  • Total revenues for the fourth quarter 2022 were $30.4 million, an increase of 24% from $24.5 million in the fourth quarter 2021.
  • R&D revenues for the fourth quarter 2022 were $7.1 million compared to $7.5 million in the fourth quarter 2021.
  • Product gross margin for the fourth quarter 2022 was 64% compared to 60% in the fourth quarter 2021, driven by changes in sales mix.
  • Selling, General & Administrative expenses for the fourth quarter 2022 were $12.3 million, compared to $11.7 million in the fourth quarter 2021.

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab

Retrieved on: 
Monday, October 3, 2022
Cancer, ADCC, Doctor of Philosophy, ADC, Neoplasm, CD205, Boehringer Ingelheim, Clinical trial, Rhode Island Division of Commercial Licensing and Regulation, Antibody-drug conjugate, CEO, Amgen, NJ, Kite Pharma, Cytotoxicity, BMS, OXFORD, SAN, Patient, OBT, Wuxi, Therapy, Vaccine, IO

Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.

Key Points: 
  • Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.
  • OBT will receive an undisclosed upfront and potential milestone payments and royalty payments on net product sales under the agreement.
  • Under the terms of the agreement, Genmab will be responsible for the future development and commercialization of any products incorporating this antibody.
  • This represents the first major license agreement for OBT's IO programs to a world leader in the field of antibody-based oncology medicines.

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab

Retrieved on: 
Monday, October 3, 2022
Cancer, ADCC, Doctor of Philosophy, ADC, Neoplasm, CD205, Boehringer Ingelheim, Clinical trial, Rhode Island Division of Commercial Licensing and Regulation, Antibody-drug conjugate, CEO, Amgen, NJ, Kite Pharma, Cytotoxicity, BMS, OXFORD, SAN, Patient, OBT, Wuxi, Therapy, Vaccine, IO

Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.

Key Points: 
  • Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.
  • OBT will receive an undisclosed upfront and potential milestone payments and royalty payments on net product sales under the agreement.
  • Under the terms of the agreement, Genmab will be responsible for the future development and commercialization of any products incorporating this antibody.
  • This represents the first major license agreement for OBT's IO programs to a world leader in the field of antibody-based oncology medicines.

Bally's Announces Marc Crisafulli, EVP Of Government Relations, Legal And Regulatory, To Retire

Retrieved on: 
Friday, September 16, 2022
IGT, Online, Tropicana Las Vegas, Time, Rhode Island Division of Commercial Licensing and Regulation, Twin River Casino, NYSE, Interactivity, OSB, Corporation, Monkey Knife Fight, Legislation, Gamesys, IGaming Business, Nature, International Game Technology, Bally's Corporation, State College, Pennsylvania, Growth, Private Securities Litigation Reform Act, Forward-looking statement, U.S. Securities and Exchange Commission, Economic development, State, Terminology, Nittany Mall, Board of directors, Leadership, Government, Retirement, Board, Security (finance), New, Craps, SEC, NV, EVP, Online gambling, Casino, Management

PROVIDENCE, R.I., Sept. 16, 2022 /PRNewswire/ -- Bally's Corporation (NYSE: BALY) today announced that Marc Crisafulli, EVP of Government Relations, Legal and Regulatory, will retire from the company, effective September 16, 2022.

Key Points: 
  • PROVIDENCE, R.I., Sept. 16, 2022 /PRNewswire/ -- Bally's Corporation (NYSE: BALY) today announced that Marc Crisafulli, EVP of Government Relations, Legal and Regulatory, will retire from the company, effective September 16, 2022.
  • Lee Fenton, Bally's Chief Executive Officer, said, "I want to thank Marc for his commitment and many contributions to Bally's over the last few years.
  • Soo Kim, Chairman of Bally's Corporation's Board of Directors, said, "Marc led a robust expansion of Bally's in recent years.
  • We look forward to building on what Marc has helped establish, and we wish him all the best in this next chapter."

Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk

Retrieved on: 
Monday, August 29, 2022
Amyotrophic lateral sclerosis, Patient, COVID-19, Legislation, NASDAQ, Rhode Island Division of Commercial Licensing and Regulation, Macimorelin, Risk, Toronto Stock Exchange, Novo Nordisk, Diagnosis, Forward-looking statement, Union, TSX, Hypoparathyroidism, Severe acute respiratory syndrome coronavirus 2, GLOBE, PD, Neuromyelitis optica spectrum disorder, Novo, Company, Therapy, FDA, News, Adult, NMOSD, Parkinson's disease, Chlamydia trachomatis, Intellectual property, U.S. FDA, European Commission, Clinical trial, Annual report, Marketing, ALS, Pharmaceutical industry, EU, Ludwig & Mayer

TORONTO, ON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Novo Nordisk Healthcare AG (“Novo Nordisk”), has exercised its right to terminate the amended development and commercialization license agreement (the “Commerical License”) previously entered into between Aeterna’s wholly-owned subsidiary and Novo for Macrilen™ (macimorelin), the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Following Novo’s 270-day notice period, Aeterna will regain full U.S. and Canadian rights to the product. Under the terms of the Commercial License, Novo Nordisk will return the regulatory approvals, the intellectual property and provide certain other assistance in order to aid in an orderly transition of Macrilen™ (macimorelin) rights to the Company. Until the end of that 270-day period, Commercial License requires Novo Nordisk to continue selling and promoting Macrilen™ (macimorelin) in the U.S., and Novo Nordisk’s financial support of the pivotal safety and efficacy DETECT-trial remains unchanged until the end of that notice period.

Key Points: 
  • Following Novos 270-day notice period, Aeterna will regain full U.S. and Canadian rights to the product.
  • We are delighted to regain full control over macimorelin in the US and Canada.
  • Macimorelin has been marketed in the U.S. by Novo Nordisk under the trade name Macrilen.
  • Under the Commercial License, Novo Nordisk was granted an exclusive license for the development, manufacturing, registration and commercialization of Macrilen (macimorelin) in the U.S. and Canada.

Codexis and Molecular Assemblies Announce Execution of Commercial License and Enzyme Supply Agreement for Optimized TdT Enzyme for Enzymatic DNA Synthesis

Retrieved on: 
Tuesday, August 2, 2022
DNA, NGS, Food, Time, GLOBE, Terminal deoxynucleotidyl transferase, U.S. Securities and Exchange Commission, Reading, Enzyme, SAN, SEC, Electronics, CEO, Research, Partnership, Private Securities Litigation Reform Act, Health, CRISPR, Oligonucleotide, NASDAQ, Gene, Rhode Island Division of Commercial Licensing and Regulation, Molecular assembler, Technology, Security (finance), Precision medicine, FES, Therapy, Annual report, Program, Gene editing, Synthetic biology, Fine chemical, Codexis

The optimized enzyme, deployed in Molecular Assemblies FES platform, is differentiated over natural enzymes on the ability to synthesize oligonucleotides of high yield and purity both critical for commercial success.

Key Points: 
  • The optimized enzyme, deployed in Molecular Assemblies FES platform, is differentiated over natural enzymes on the ability to synthesize oligonucleotides of high yield and purity both critical for commercial success.
  • This commercial license and supply agreement puts Molecular Assemblies in a position to achieve our commercialization objectives ahead of schedule.
  • The financial terms of the agreement include milestone payments from Molecular Assemblies to Codexis and royalties on sales of oligonucleotides synthesized using FES technology.
  • Under the terms of the agreement, Molecular Assemblies has exclusively licensed the Codexis evolved TdT enzyme for commercial use in DNA synthesis.

CHARBONE Hydrogen Announces the Execution of a Term Sheet With GAUSSIN to Manufacture and Commercialize Hydrogen Vehicles in Canada

Retrieved on: 
Tuesday, May 24, 2022
CEO, Engineering, News, TSX Venture Exchange, Montagne du Charbon, Solution, Rhode Island Division of Commercial Licensing and Regulation, Marketing, Legislation, Airport, CH, Partnership, Negotiation, Technology, Sale, International joint venture, Euronext Growth, GLOBE, Acquisition, Term sheet, Renewable energy

The delivery of the Term Sheet remains subject to the execution, between GAUSSIN and Charbone, of a 20-year definitive license agreement with right to sublicense (theManufacturing and Commercial License Agreement) by June 22, 2022.

Key Points: 
  • The delivery of the Term Sheet remains subject to the execution, between GAUSSIN and Charbone, of a 20-year definitive license agreement with right to sublicense (theManufacturing and Commercial License Agreement) by June 22, 2022.
  • It demonstrates once again the group's pioneering spirit, which will enable the manufacture of high-tech and clean vehicles in Canada.
  • With more than 50,000 vehicles worldwide, GAUSSIN enjoys a strong reputation in four fast-expanding markets: port terminals, airports, logistics and people mobility.
  • Except as required under applicable securities legislation, Charbone undertakes no obligation to publicly update or revise forward-looking information.

Rhode Island Superior Court clears the way for PPL's acquisition of Narragansett Electric following PPL settlement agreement with Rhode Island attorney general

Retrieved on: 
Monday, May 23, 2022
Rhode Island Superior Court, PPL Corporation, PPL, Natural gas, National Grid plc, Leadership, Electricity, News, Information technology, Rhode Island Division of Commercial Licensing and Regulation, Superior court, Sorgi, Public utility, Carrier, National Grid, Time, Lifting, Climate, Acquisition, Growth, NYSE, Online gambling, Renewable energy

ALLENTOWN, Pa., May 23, 2022 /PRNewswire/ -- The Rhode Island Superior Court today cleared the way for PPL Corporation (NYSE: PPL) to acquire The Narragansett Electric Company from National Grid USA following a settlement agreement between PPL and the Rhode Island attorney general's office.

Key Points: 
  • ALLENTOWN, Pa., May 23, 2022 /PRNewswire/ -- The Rhode Island Superior Court today cleared the way for PPL Corporation (NYSE: PPL) to acquire The Narragansett Electric Company from National Grid USA following a settlement agreement between PPL and the Rhode Island attorney general's office.
  • The Superior Court issued orders dismissing the attorney general's appeal of an earlier order from the Rhode Island Division of Public Utilities and Carriers approving the acquisition and lifting the court's stay of the approval order.
  • As part of PPL's settlement agreement with the attorney general, PPL has agreed to:
    Provide $50 million in bill credits to Narragansett Electric customers, both gas and electric.
  • Forgo the potential recovery of transition costs associated with the acquisition and integration of Narragansett Electric, which PPL had already capped in its prior commitments.